VIRIOS THERAPEUTICS INC (VIRI) 0.3566 +0.02 (+6.42%)
0.3566 +0.02 (+6.42%)
US92829J1043 - Common Stock - After market: 0.3567 +0 (+0.03%)
Fundamental Rating
We assign a fundamental rating of 2 out of 10 to VIRI. VIRI was compared to 641 industry peers in the Biotechnology industry. VIRI has a bad profitability rating. Also its financial health evaluation is rather negative. VIRI has a expensive valuation and it also scores bad on growth
Note: VIRI has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
VIRI has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of VIRI.
VS Industry
Valuation
Valuation Rating
When comparing the current price to the book value of VIRI, it is valued rather cheaply. It is trading at 0.71 times its book value.
When comparing the price book ratio of VIRI to the average industry price book ratio of 1.91, VIRI is valued rather cheaply.
The Price/Earnings Ratio is negative for VIRI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIRI. No positive earnings are expected for the next year.
VS Industry
Price/Book (0.71) VS Industry: 78% outperformed.
440.81
0.07
Growth
Growth Rating
VIRI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.59%, which is quite impressive.
Based on estimates for the next 5 years, VIRI will show a small growth in Earnings Per Share. The EPS will grow by 9.52% on average per year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 33.59% | 42.44% | 28.21% | 19.69% | 9.52% |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
A Current Ratio of 6.65 indicates that VIRI has no problem at all paying its short term obligations.
VIRI has a Quick Ratio of 6.65. This indicates that VIRI is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio is in line with the industry averages, which is at 6.18.
The Quick Ratio is in line with the industry averages, which is at 6.05.
The Debt to Equity ratio of VIRI is in line with the industry averages.
Based on the Altman-Z score of -8.08, we must say that VIRI is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.14, VIRI is in worse financial state than most of its industry peers. 81% of its industry peers have a better Altman-Z score.
The Piotroski-F score of VIRI is 3.00. This is a low score and indicates issues in the health and profitability of VIRI.
VS Industry
Debt/Equity (0) VS Industry: 42% outperformed.
15.37
0.00
Quick Ratio (6.65) VS Industry: 54% outperformed.
0.04
84.53
Current Ratio (6.65) VS Industry: 54% outperformed.
0.08
85.09
Altman-Z (-8.08) VS Industry: 19% outperformed.
-2,797.49
667.93
Dividend
Dividend Rating
VIRI does not give a dividend.
VIRIOS THERAPEUTICS INC0.3566
NASDAQ:VIRI (2/7/2023, 7:12:35 PM)+0.02 (+6.42%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 11-14 2022-11-14/bmo | Earnings (Next) | N/A N/A |
| Inst Owners | 6.95% | Inst Owner Change | -1.25% |
| Ins Owners | 4.07% | Ins Owner Change | -0.24% |
| Market Cap | 6.54M | Analysts | 43.33 |
| Price Target | 2.04 (472.07%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Dividend Growth(5Y) | N/A | DP | N/A |
| Div Incr Years | N/A | Div Non Decr Years | N/A |
| Ex-Date | N/A | ||
| EPS beat(2) | 2 | Avg EPS beat(2) | 29.28% |
| Min EPS beat(2) | 14.58% | Max EPS beat(2) | 43.98% |
| EPS beat(4) | 4 | Avg EPS beat(4) | 23.04% |
| Min EPS beat(4) | 12.04% | Max EPS beat(4) | 43.98% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | N/A |
| Min Revenue beat(2) | N/A | Max Revenue beat(2) | N/A |
| Revenue beat(4) | N/A | Avg Revenue beat(4) | N/A |
| Min Revenue beat(4) | N/A | Max Revenue beat(4) | N/A |
| PT rev (1m) | 0% | PT rev (3m) | 0% |
| EPS NQ rev (1m) | 0% | EPS NQ rev (3m) | 68.69% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | 37.89% |
| Revenue NQ rev (1m) | N/A | Revenue NQ rev (3m) | N/A |
| Revenue NY rev (1m) | N/A | Revenue NY rev (3m) | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.71 | ||
| P/tB | 0.71 | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -1.74 | EY | N/A |
| EPS(NY) | -0.74 | Fwd EY | N/A |
| FCF(TTM) | -0.76 | FCFY | N/A |
| OCF(TTM) | -0.76 | OCFY | N/A |
| SpS | N/A | BVpS | 0.5 |
| TBVpS | 0.5 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | N/A |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | N/A | GM growth 5Y | N/A |
| F-Score | 3 | Asset Turnover | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.65 | ||
| Quick Ratio | 6.65 | ||
| Altman-Z | -8.08 |
| F-Score | 3 | WACC | N/A |
| ROIC/WACC | N/A | Cap/Depr(3y) | N/A |
| Cap/Depr(5y) | N/A | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | 33.59% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 42.86% |
| EPS Next Y | 42.44% | EPS Next 2Y | 28.21% |
| EPS Next 3Y | 19.69% | EPS Next 5Y | 9.52% |
| Revenue growth 1Y | N/A | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| EBIT growth 1Y | 19.37% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | N/A |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | -571.85% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | -571.85% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA